RecruitingPhase 1NCT06999434

Exploring the Utility of [18F]3F4AP for Demyelination Imaging


Sponsor

Yale University

Enrollment

105 participants

Start Date

May 5, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a new PET scan radiotracer — a small amount of a mildly radioactive substance injected into the body — can help detect damage to the protective covering of nerve cells (called demyelination) in conditions like multiple sclerosis. **You may be eligible if...** - You are between 18 and 89 years old - You are in generally good health - You are able to understand and sign an informed consent form **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have a significant illness or unstable medical condition - You have claustrophobia or other conditions that make lying in a PET scanner difficult - You have had significant radiation exposure from research scans in the past 12 months - You have a bleeding disorder or take blood thinners Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[ 18F]3F4AP

PET Scan #3

DRUG[18F]MK6240

PET Scan #2

DRUG[11C]PIB

PET Scan #1


Locations(1)

Yale University PET Center

New Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06999434


Related Trials